A new kind of black hole analog could tell us a thing or two about an elusive radiation theoretically emitted by the real thing.
Using a chain of atoms in single-file to simulate the event horizon of a black hole, a team of physicists has observed the equivalent of what we call Hawking radiation – particles born from disturbances in the quantum fluctuations caused by the black hole’s break in spacetime.
This, they say, could help resolve the tension between two currently irreconcilable frameworks for describing the Universe: the general theory of relativity, which describes the behavior of gravity as a continuous field known as spacetime; and quantum mechanics, which describes the behavior of discrete particles using the mathematics of probability.
Hypothetical bridges connecting distant regions of space (and time) could more or less look like garden variety black holes, meaning it’s possible these mythical beasts of physics have already been seen.
Thankfully however, if a new model proposed by a small team of physicists from Sofia University in Bulgaria is accurate, there could still be a way to tell them apart.
Play around with Einstein’s general theory of relativity long enough, it’s possible to show how the spacetime background of the Universe can form not only deep gravitational pits where nothing escapes – it can form impossible mountain peaks which can’t be climbed.
Frank Close tells the human story of how we solved The Infinity Puzzle – once the bane of physics
INFINITY. In mathematics, it’s a curiosity. In physics, it’s a disease. It reared its head back in the 1940s, with quantum electrodynamics (QED), the theory of electromagnetism.
A group of scientists from Aalto University, IQM Quantum Computers, and VTT Technical Research Center have discovered a new superconducting qubit, the unimon, to increase the accuracy of quantum computations. The team has achieved the first quantum logic gates with unimons at 99.9% fidelity—a major milestone on the quest to build commercially useful quantum computers. This research was just published in the journal Nature Communications.
Of all the different approaches to build useful quantum computers, superconducting qubits are in the lead. However, the qubit designs and techniques currently used do not yet provide high enough performance for practical applications. In this noisy intermediate-scale quantum (NISQ) era, the complexity of the implementable quantum computations is mostly limited by errors in single-and two-qubit quantum gates. The quantum computations need to become more accurate to be useful.
“Our aim is to build quantum computers which deliver an advantage in solving real-world problems. Our announcement today is an important milestone for IQM, and a significant achievement to build better superconducting quantum computers,” said Professor Mikko Möttönen, joint Professor of Quantum Technology at Aalto University and VTT, and also a Co-Founder and Chief Scientist at IQM Quantum Computers, who was leading the research.
The mathematician shares his latest theories on quantum consciousness, the structure of the universe and how to communicate with civilisations from other cosmological aeons.
The timing of this fresh wave of Russian attacks is not lost on anybody, coming hours after President Zelenskyy addressed world leaders meeting in Bali for the G20.
Deepfakes, which usually involve superimposing someone’s face and voice onto another person, started gaining attention a few years ago when adult websites began banning videos where the technique was used to add famous actresses’ faces to porn stars’ bodies.
Advancing Novel Therapeutic Interventions For Unmet Medical Needs — Dr. Michael Hufford, Ph.D., Co-Founder and CEO, LyGenesis; Interim CEO, Morphoceuticals; Scientific Advisor, Juvenescence.
Dr. Michael Hufford, Ph.D. is the Co-Founder and the Chief Executive Officer of LyGenesis (https://www.lygenesis.com/), a clinical-stage cell therapy company that transforms patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. He also serves as the Interim CEO of Morphoceuticals (https://www.morphoceuticals.com/) a company focused on modifying electric potentials in cells and tissues for a variety of applications in regenerative medicine, from improving amputation stump health and limb regeneration, to organogenesis, to creating a bioelectric atlas where numerous disease indications may be corrected.
Dr. Hufford also serves as a scientific advisor to Juvenescence (https://juvlabs.com/) a biotech holding company that develops therapies and products to modify aging and help people live longer.
An entrepreneur and drug developer, Dr. Hufford has over 20 years of experience in the development and FDA regulatory approval of small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has designed and executed clinical trials and drug development programs across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatric and oncology indications. His experience in-and out-licensing pre-clinical and clinical stage assets, executing corporate partnering deals, and in investor relations, has helped him to raise public, private, and angel-back financing for his companies. His philanthropic work includes co-founding and serving as the CEO of Harm Reduction Therapeutics, Inc. (https://www.harmreductiontherapeutics.org/), a nonprofit pharmaceutical company developing low-cost over-the-counter intra-nasal naloxone in the US to help prevent opioid overdose deaths.
Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master’s and doctoral degrees in Clinical Psychology from the University of Pittsburgh, before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is an award-winning lecturer, and the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents.
The patients had some, although severely diminished, visual function during the day, however, at night they were essentially blind, with light sensitivity 10,000–100,000 times less than normal.
According to researchers at the Scheie Eye Institute at the Perelman School of Medicine at the University of Pennsylvania, adults with a genetic form of childhood-onset blindness experienced remarkable recoveries of night vision within days of receiving an experimental gene therapy.
The patients had Leber Congenital Amaurosis (LCA), a congenital blindness caused by GUCY2D gene mutations. The findings were published in the journal iScience. The researchers administered AAV gene therapy, which contains the DNA.
